Fujifilm Corporation's LIfe Sciences Group companies, including Fujifilm Irvine Scientific and Fujifilm Biosciences, have rebranded as part of a strategic positioning effort.
Through this rebrand, the company's Irvine Scientific division will become Fujifilm Biosciences, which reflects its recent expansion to serve broader life science communities.
According to the group, Fujifilm Biosciences has evolved significantly during its past 55 years of operations, with the company now offering a comprehensive portfolio of discovery and research reagents, recombinant growth factors and proteins, specialty chemicals, critical assay materials and US-specific cell culture media solutions.
The new brand name will take effect immediately, though the company's name will legally change from the start of 2026.
Meanwhile, the group's contract development and manufacturing organisation (CDMO) Fujifilm Diosynth Biotechnologies will rebrand to Fujifilm Biotechnologies — though the company's legal name will not change.
Fujifilm Biotechnologies will continue to service its global customers, offering a wide range of services from process development to commerical supply throughout Europe and the US.
During the last 15 years, Fujifilm has invested more than $10bn into its operations through both expansions and acquisitions, allowing it to build its end-to-end life sciences capabilities.
“Under the ‘Partners for Life’ umbrella, our Life Sciences Group companies offer complete solutions to the pharmaceutical and biotechnology markets, aligning with both our strategic growth plans and commitment to innovation,” commented Toshihisa Iida, Director, Corporate VP and General Manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation.
“By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector, where we believe that unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum."
“At FUJIFILM Biotechnologies, we take immense pride in the value we bring to our partners everyday to help bring life-changing medicines to patients,” said Lars Petersen, President and CEO of FUJIFILM Biotechnologies.
“This closer coordination and united focus strengthens how we interact and deliver for our customers. Together, we offer deep knowledge and experience, speed, flexibility, and scientific rigor—critical elements in bringing complex biologics to life.”
Alongside Fujifilm Biosciences and Fujifilm Biotechnologies, the Fujifilm Life Sciences Group companies also include Fujifilm Cellular Dynamics, a developer and manufacturer of human induced pluripotent stem cells, Fujifilm Wako Pure Chemical Corporation, and Fujifilm Toyama Chemical.